MX2017005346A - Nuevos compuestos de piridopirimidinona para modular la actividad catalitica de histona lisina desmetilasas (kdm). - Google Patents
Nuevos compuestos de piridopirimidinona para modular la actividad catalitica de histona lisina desmetilasas (kdm).Info
- Publication number
- MX2017005346A MX2017005346A MX2017005346A MX2017005346A MX2017005346A MX 2017005346 A MX2017005346 A MX 2017005346A MX 2017005346 A MX2017005346 A MX 2017005346A MX 2017005346 A MX2017005346 A MX 2017005346A MX 2017005346 A MX2017005346 A MX 2017005346A
- Authority
- MX
- Mexico
- Prior art keywords
- modulating
- kdms
- catalytic activity
- histone lysine
- compounds
- Prior art date
Links
- 102000008157 Histone Demethylases Human genes 0.000 title abstract 2
- 108010074870 Histone Demethylases Proteins 0.000 title abstract 2
- IAAQUOVTPAMQCR-UHFFFAOYSA-N 1h-pyrido[3,2-d]pyrimidin-2-one Chemical class C1=CC=C2NC(=O)N=CC2=N1 IAAQUOVTPAMQCR-UHFFFAOYSA-N 0.000 title 1
- 230000003197 catalytic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462069915P | 2014-10-29 | 2014-10-29 | |
| PCT/KR2015/011386 WO2016068580A2 (en) | 2014-10-29 | 2015-10-27 | Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017005346A true MX2017005346A (es) | 2017-08-02 |
Family
ID=55851908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017005346A MX2017005346A (es) | 2014-10-29 | 2015-10-27 | Nuevos compuestos de piridopirimidinona para modular la actividad catalitica de histona lisina desmetilasas (kdm). |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9834550B2 (enExample) |
| EP (1) | EP3212647B1 (enExample) |
| JP (1) | JP6505222B2 (enExample) |
| KR (1) | KR101978899B1 (enExample) |
| CN (1) | CN107001358A (enExample) |
| AU (1) | AU2015340215B2 (enExample) |
| BR (1) | BR112017008312A2 (enExample) |
| CA (1) | CA2962917C (enExample) |
| MX (1) | MX2017005346A (enExample) |
| NZ (1) | NZ730475A (enExample) |
| RU (1) | RU2684396C2 (enExample) |
| SG (1) | SG11201702075QA (enExample) |
| WO (1) | WO2016068580A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6853819B2 (ja) * | 2015-10-08 | 2021-03-31 | スーチョウ ユンシュアン イーヤオ カジ ヨウシェン ゴンス | Ｗｎｔシグナル伝達経路阻害剤およびその治療用途 |
| US10221191B2 (en) | 2015-12-22 | 2019-03-05 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| SG11201911929XA (en) | 2017-06-21 | 2020-01-30 | SHY Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| WO2020011086A1 (zh) * | 2018-07-13 | 2020-01-16 | 四川科伦博泰生物医药股份有限公司 | 苯并二氮杂环类化合物、其制备方法及用途 |
| WO2020132071A1 (en) | 2018-12-19 | 2020-06-25 | Shy Therapeutics. Llc | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease |
| EP4098650B1 (en) | 2020-01-31 | 2025-12-10 | Kumiai Chemical Industry Co., Ltd. | 3-alkoxy benzoic acid amide derivative, and pest control agent |
| EP4126847A1 (en) | 2020-03-30 | 2023-02-08 | ENYO Pharma | Quinazolinone derivatives and uses thereof for treating a cancer |
| WO2021198191A1 (en) | 2020-03-30 | 2021-10-07 | Enyo Pharma | Quinazolinone derivatives and uses thereof for treating a cancer |
| JP7768592B2 (ja) * | 2021-03-31 | 2025-11-12 | デューク ストリート バイオ リミテッド | 医薬化合物 |
| GB202114315D0 (en) * | 2021-10-06 | 2021-11-17 | Duke Street Bio Ltd | Pharmaceutical compound |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5939421A (en) * | 1997-07-01 | 1999-08-17 | Signal Pharmaceuticals, Inc. | Quinazoline analogs and related compounds and methods for treating inflammatory conditions |
| GB9909135D0 (en) * | 1999-04-22 | 1999-06-16 | Univ Wales Medicine | Cystic fibrosis medicaments |
| WO2003045911A1 (en) * | 2001-11-26 | 2003-06-05 | Dsm Ip Assets B.V. | Process for recovering caprolactam |
| FR2846657B1 (fr) | 2002-11-05 | 2004-12-24 | Servier Lab | Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2005032481A2 (en) * | 2003-09-30 | 2005-04-14 | Scios Inc. | Quinazoline derivatives as medicaments |
| NZ546477A (en) | 2006-04-07 | 2009-04-30 | Auckland Uniservices Ltd | 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy |
| EP2734520B1 (en) * | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| AU2013323360B2 (en) * | 2012-09-28 | 2017-09-07 | Cancer Research Technology Limited | Azaquinazoline inhibitors of atypical protein kinase C |
| US20150272939A1 (en) | 2012-10-02 | 2015-10-01 | Yale University | Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase |
| HRP20170358T1 (hr) | 2012-10-02 | 2017-04-21 | Gilead Sciences, Inc. | Inhibitori histonskih demetilaza |
| WO2014087165A1 (en) * | 2012-12-06 | 2014-06-12 | University Of Bath | Tankyrase inhibitors |
| ES2670864T3 (es) | 2013-02-27 | 2018-06-01 | Gilead Sciences, Inc. | Inhibidores de histonas desmetilasas |
| WO2014164708A1 (en) | 2013-03-12 | 2014-10-09 | Quanticel Pharmaceuticals, Inc. | Histone dementhylase inhibitors |
| EP2970307B1 (en) | 2013-03-13 | 2020-03-11 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
| PL2970211T3 (pl) | 2013-03-15 | 2018-01-31 | Quanticel Pharmaceuticals Inc | Inhibitory demetylazy histonowej |
| EP3041474B1 (en) | 2013-09-05 | 2020-03-18 | Genentech, Inc. | Antiproliferative compounds |
| CN103694255A (zh) * | 2014-01-09 | 2014-04-02 | 华中师范大学 | 吡啶并噁嗪酮和吡啶并嘧啶酮类化合物及其制备方法与应用 |
| TWI675836B (zh) * | 2014-03-25 | 2019-11-01 | 美商伊格尼塔公司 | 非典型蛋白質激酶ｃ之氮雜喹唑啉抑制劑 |
-
2015
- 2015-10-27 CA CA2962917A patent/CA2962917C/en active Active
- 2015-10-27 NZ NZ730475A patent/NZ730475A/en unknown
- 2015-10-27 EP EP15853996.5A patent/EP3212647B1/en not_active Not-in-force
- 2015-10-27 JP JP2017523293A patent/JP6505222B2/ja not_active Expired - Fee Related
- 2015-10-27 RU RU2017113007A patent/RU2684396C2/ru active
- 2015-10-27 BR BR112017008312A patent/BR112017008312A2/pt not_active Application Discontinuation
- 2015-10-27 WO PCT/KR2015/011386 patent/WO2016068580A2/en not_active Ceased
- 2015-10-27 KR KR1020177014472A patent/KR101978899B1/ko active Active
- 2015-10-27 AU AU2015340215A patent/AU2015340215B2/en active Active
- 2015-10-27 CN CN201580061545.6A patent/CN107001358A/zh active Pending
- 2015-10-27 SG SG11201702075QA patent/SG11201702075QA/en unknown
- 2015-10-27 US US14/923,525 patent/US9834550B2/en active Active
- 2015-10-27 MX MX2017005346A patent/MX2017005346A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015340215B2 (en) | 2018-11-15 |
| SG11201702075QA (en) | 2017-04-27 |
| CA2962917C (en) | 2019-04-30 |
| KR20170072943A (ko) | 2017-06-27 |
| RU2684396C2 (ru) | 2019-04-09 |
| CN107001358A (zh) | 2017-08-01 |
| US20160122343A1 (en) | 2016-05-05 |
| WO2016068580A3 (en) | 2016-08-18 |
| EP3212647A4 (en) | 2018-04-18 |
| EP3212647A2 (en) | 2017-09-06 |
| AU2015340215A1 (en) | 2017-04-13 |
| US9834550B2 (en) | 2017-12-05 |
| NZ730475A (en) | 2018-09-28 |
| RU2017113007A3 (enExample) | 2018-11-29 |
| RU2017113007A (ru) | 2018-11-29 |
| KR101978899B1 (ko) | 2019-05-15 |
| CA2962917A1 (en) | 2016-05-06 |
| JP2017533215A (ja) | 2017-11-09 |
| WO2016068580A2 (en) | 2016-05-06 |
| JP6505222B2 (ja) | 2019-04-24 |
| EP3212647B1 (en) | 2019-04-03 |
| BR112017008312A2 (pt) | 2017-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ730475A (en) | Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms) | |
| PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
| TW201613911A (en) | Heterocyclic compounds and uses thereof | |
| PH12017501306A1 (en) | Inhibitors of histone demethylases | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| GEP20186887B (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| PH12016500467A1 (en) | Aminoheteroarlyl benzamides as kinase inhibitors | |
| BR112016015706A8 (pt) | composto, uso do mesmo e composição farmacêutica | |
| PH12015501996A1 (en) | Heterocyclic compounds and uses thereof | |
| MX380394B (es) | Compuesto novedoso de bifenilo o una sal del mismo. | |
| EA201591632A1 (ru) | Цитотоксические и антимитотические соединения и способы их применения | |
| MX2017003233A (es) | Compuestos y composiciones como inhibidores de quinasa raf. | |
| GEP201706725B (en) | Compounds and compositions as inhibitors of mek | |
| PH12016501462A1 (en) | Neprilysin inhibitors | |
| PH12017500533A1 (en) | 1-alkyl-6-oxo-1, 6-dihydropyridin-3-yl compounds and use as sgrm modulators | |
| EA201791219A1 (ru) | Антибактериальные композиции, имеющие широкий спектр активности | |
| BR112016024235A2 (pt) | composições farmacêuticas compreendendo agentes antibacterianos | |
| EA201890906A1 (ru) | ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
| PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| MX2015016332A (es) | Inhibidores de alk biciclicos fusionados. | |
| MY180006A (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| BR112016024236A2 (pt) | composições farmacêuticas compreendendo agentes antibacterianos | |
| MX2016005539A (es) | Composiciones farmaceuticas que comprenden agentes antibacterianos. | |
| EA201690673A1 (ru) | Комбинированная терапия лахинимодом для лечения рассеянного склероза |